Carl Gordon Insider Profile

39 Followers
Carl Gordon, Director at Intellia Therapeutics, holds ― shares in Intellia Therapeutics (Ticker: NTLA), holds 3.81M shares in MBX Biosciences, Inc. (Ticker: MBX), holds 119.52K shares in Keros Therapeutics (Ticker: KROS). Most recently, Carl Gordon ― shares of Intellia Therapeutics on ― for an estimated value of ―.
tipranks
Carl Gordon

Carl Gordon
Intellia Therapeutics (NTLA)
Director

Ranked #54,413 out of 99,218 Corporate Insiders

Profitable Transactions

46%
12 out of 26 Profitable Transactions

Average Return

-1.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$300M
29.11%
17.25%
16.26%
11.27%
26.11% Others
A breakdown of Carl Gordon's holdings

Insider Roles

MBX Biosciences, Inc.
(MBX)
Director, Ten Percent Owner
ArriVent BioPharma, Inc.
(AVBP)
Director, Ten Percent Owner
Pacira Pharmaceuticals
(PCRX)
Director
Compass Therapeutics
(CMPX)
Director, Ten Percent Owner
+11 other positions
Roles that Carl Gordon holds in companies

Most Profitable Insider Trade

Stock:
Keros Therapeutics
(KROS)
Rating:Informative Buy
Date:Apr 13, 2020 - Apr 13, 2021
Return:+175.70%
The most profitable trade made by Carl Gordon

Carl Gordon's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Intellia Therapeutics
Director
X4 Pharmaceuticals
Nov 20, 2017
Director
Informative Buy
5.00M
$1.15M
ARMO
Armo Biosciences Inc
Jun 22, 2018
Uninformative Sell
205.95M
$0.00
Alector
Feb 11, 2019
Director, Ten Percent Owner
Uninformative Buy
$1.17M
TPTX
Turning Point Therapeutics
Apr 24, 2019
Informative Buy
6.48M
$154.11M
PRVL
Prevail Therapeutics
Jun 26, 2019
Informative Buy
15.00M
$317.92M
Keros Therapeutics
Aug 15, 2024
Director
Informative Sell
11.00M
$8.12M
Oric Pharmaceuticals
Mar 31, 2021
Director, Ten Percent Owner
Uninformative Sell
2.43M
$22.70M
Adicet Bio
Jun 07, 2024
Director, Ten Percent Owner
Uninformative Buy
$15.01M
KNTE
Kinnate Biopharma
Apr 05, 2024
Uninformative Sell
$0.00
Terns Pharmaceuticals
Jul 17, 2024
Director, Ten Percent Owner
Informative Sell
561.64K
$5.52M
Disc Medicine
Director, Ten Percent Owner
THRX
Theseus Pharmaceuticals
Feb 14, 2024
Uninformative Sell
$0.00
Compass Therapeutics
Nov 10, 2022
Director, Ten Percent Owner
Informative Buy
1.29M
$33.82M
ArriVent BioPharma, Inc.
Jan 31, 2024
Director, Ten Percent Owner
Uninformative Buy
$51.75M
MBX Biosciences, Inc.
Sep 17, 2024
Director, Ten Percent Owner
Uninformative Buy
$87.34M
Pacira Pharmaceuticals
Feb 10, 2011
Director
Informative Buy
13.33M
$48.77M
ACADIA Pharmaceuticals
Director
$24.65M
XLRN
Acceleron Pharma
Sep 18, 2013
Uninformative Buy
$1.43M
Amarin
Sep 05, 2012
Director
Uninformative Sell
3.37M
$3.27K
BioCryst
Director
$0.00
~GNOM
Complete Genomics
List of latest transactions for each holding click on a transaction to see Carl Gordon's performance on stock

Carl Gordon insider profile FAQ

What is the percentage of profitable transactions made by Carl Gordon?
The percentage of profitable transactions made by Carl Gordon is 46%.
    What is the average return per transaction made by Carl Gordon?
    The average return per transaction made by Carl Gordon is -1.10%.
      What stocks does Carl Gordon hold?
      Carl Gordon holds: NTLA, XFOR, ARMO, ALEC, TPTX, PRVL, KROS, ORIC, ACET, KNTE, TERN, IRON, THRX, CMPX, AVBP, MBX, PCRX, ACAD, XLRN, AMRN, BCRX, ~GNOM stocks.
        What was Carl Gordon’s latest transaction?
        Carl Gordon latest transaction was an Uninformative Buy of ―.
          What was Carl Gordon's most profitable transaction?
          Carl Gordon’s most profitable transaction was an Informative Buy of KROS stock on April 13, 2020. The return on the trade was 175.70%.
            What is Carl Gordon's role in Intellia Therapeutics?
            Carl Gordon's role in Intellia Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.